Advanced Renal Cell Carcinoma: Future Treatment Paradigms and Emerging Therapeutic Strategies

Dr. Monty Pal concludes the program by discussing how the treatment landscape for advanced renal cell carcinoma (RCC) may evolve as new clinical evidence emerges. He reviews recent studies evaluating novel frontline treatment strategies, including triplet therapy, and explains why doublet regimens remain the current standard of care based on available evidence. Dr. Pal emphasizes the continued importance of clinical trial participation to advance treatment options and highlights ongoing research investigating microbiome-modulating approaches and novel immunotherapy combinations. He also discusses the promise of emerging bispecific antibodies and other investigational therapies that may reshape the management of patients with relapsed disease in the future. Reflecting on current clinical practice, Dr. Pal reinforces that treatment sequencing should remain individualized, balancing efficacy, tolerability, and patient-specific considerations while selecting the most appropriate therapy at each stage of the disease. He closes by summarizing the key principles discussed throughout the program and encouraging clinicians to apply evidence-based, patient-centered treatment strategies in the management of advanced renal cell carcinoma.